Literature DB >> 2527286

Enzyme-linked immunoassay for Lp[a].

G M Fless1, M L Snyder, A M Scanu.   

Abstract

Based on our findings that rabbit antisera raised against human Lp[a] or apo[a] have the potential to cross-react with plasminogen, and in some cases have nearly equal affinities for plasminogen and Lp[a], we have developed an assay for plasma Lp[a] based on a "sandwich" ELISA that is insensitive to the presence of plasminogen. This was accomplished through the use of anti-apo[a] as a capture antibody and quantitation of the bound Lp[a], i.e., the apoB-100-apo[a] complex, with an anti-apoB antibody. Although apo[a] is heterogeneous in size, all Lp[a] particles tested, either in pure form or contained in whole plasma, gave parallel dose-response curves and were immunologically equivalent. However, when purified Lp[a] particles with different apo[a] isoforms were studied, those having larger isoforms were, on a weight basis, less reactive than those having a smaller size. Nearly equivalent reactivity was observed when protein concentration was expressed on a molar basis. The distribution of Lp[a] in a population of 84 subjects was skewed with one-third of the individuals having less than 1 mg/dl Lp[a] protein. All subjects tested had measurable concentrations of Lp[a] with a lower limit of detection of 0.030 mg/dl Lp[a] protein. The mean level was 3.2 mg/dl with a range of 0.045 to 13.3 mg/dl. These studies demonstrate the successful development of an ELISA for Lp[a] protein that is insensitive to the presence of plasminogen; that heterogeneity of Lp[a] and apo[a] are an important source of variation in the assay; and the need for an appropriate Lp[a] standard in order to minimize this variation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527286

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  14 in total

1.  The genetic dissection of complex traits in a founder population.

Authors:  C Ober; M Abney; M S McPeek
Journal:  Am J Hum Genet       Date:  2001-10-03       Impact factor: 11.025

2.  Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a).

Authors:  C Sandholzer; G Feussner; J Brunzell; G Utermann
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

3.  Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes.

Authors:  O Klezovitch; C Edelstein; A M Scanu
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 4.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay.

Authors:  R W Evans; S S Sankey; B A Hauth; K Sutton-Tyrrell; M I Kamboh; L H Kuller
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

6.  Variation in ITGB3 has sex-specific associations with plasma lipoprotein(a) and whole blood serotonin levels in a population-based sample.

Authors:  Lauren A Weiss; Mark Abney; Rodney Parry; Angelo M Scanu; Edwin H Cook; Carole Ober
Journal:  Hum Genet       Date:  2005-04-15       Impact factor: 4.132

Review 7.  The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events.

Authors:  A M Scanu
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

8.  The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.

Authors:  D J Rader; W Cain; K Ikewaki; G Talley; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production.

Authors:  D J Rader; W Cain; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.

Authors:  Angelo M Scanu; Janet Hinman
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.